Starpharma Receives First Payment Under Multi-Product DEP® licence

Starpharma Holdings Limited (ASX: SPL) announces that AstraZeneca has commenced phase 1 first-in human clinical trial for AZD0466.

·         AstraZeneca, which utilises the proprietary DEP® of Starpharma, is a highly optimised nanomedicine formulation of a novel dual Bcl2/xL inhibitor;

·         The first administration of AZD0466 triggered the first payment of USD 3 million under its multi-product DEP® licence with AstraZeneca.

·         AstraZeneca, which utilises the proprietary DEP® of Starpharma, is a highly optimised nanomedicine formulation of a novel dual Bcl2/xL inhibitor;

·         The first administration of AZD0466 triggered the first payment of USD 3 million under its multi-product DEP® licence with AstraZeneca.

-->

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK